4月29日，圣湘生物科技股份有限公司发布2024年年度报告，数据显示，公司在营收规模持续扩张的同时，利润结构呈现分化态势。报告期内，公司实现营 业收入14.58亿元，同比增长44.78%；扣除非经常性损益后的净利润2.02亿元，同比大幅增长182.25%，但归属于母公司股东的净利润同比下降24.23%。这一 数据背后，既反映出企业通过产品结构优化实现的主业盈利能力提升，也暴露出诊断仪器业务萎缩、非经常性收益波动等深层次挑战。 然而，营收扩张并未完全转化为净利润增长。2024年归母净利润同比下降24.23%至2.76亿元，主要受非经常性损益波动影响。具体而言，公司的非经常性损 益大幅减少，其中政府给予的扶持资金减少，以及投资所获得的收益降低，都是重要原因。这种营收增长与净利润下降的反差，充分暴露出企业的利润构成 存在问题，过度依赖外部补贴以及资本运作带来的收益，自身核心业务创造利润的能力有待加强。 诊断仪器毛利率跌至-18%：成本压力与技术迭代挑战 与诊断试剂业务的强势增长形成鲜明对比，诊断仪器板块成为公司业绩的拖累项。2024年该业务收入仅0.83亿元，同比下滑43.82%，毛利率更是跌 至-18.23%，较 ...

Core Viewpoint - The company, Sansure Biotech, reported strong financial performance for 2024, with significant revenue growth and a commitment to shareholder returns through cash dividends [1][9]. Financial Performance - In 2024, Sansure Biotech achieved a revenue of 1.458 billion yuan, representing a year-on-year growth of 44.78% [1] - The net profit attributable to shareholders was 276 million yuan, with a non-recurring net profit of 202 million yuan, showing a remarkable increase of 182.25% [1] - The company plans to distribute a cash dividend of 2.75 yuan per share, totaling approximately 158 million yuan, contributing to a cumulative dividend exceeding 300 million yuan for the year [1][9] Research and Development - The total R&D investment for the year reached 361 million yuan, a 53.36% increase, accounting for 24.79% of revenue [2] - The company obtained over 200 new domestic and international registration certificates and patents, with a total of more than 1,600 certificates acquired [2] Product Development - In the respiratory disease sector, the company launched several nucleic acid testing reagents, enhancing its product ecosystem in respiratory health [2] - The company made significant advancements in women's health, with a nearly 50% increase in HPV product shipments and the certification of a comprehensive cervical cancer screening product [2][3] Strategic Acquisitions - In early 2025, Sansure Biotech announced a series of acquisitions, including an 807.5 million yuan purchase of a 100% stake in Zhongshan Haiji, entering the biopharmaceutical growth hormone sector [4] - The company also invested 75.6 million yuan for a 54% stake in Hong'an Jiyuan, targeting the blood cell analyzer market [4] Digital Transformation - The company is actively pursuing digital transformation in healthcare, launching a smart infectious disease system that integrates various digital technologies [5] - This system aims to enhance disease prevention and control through automated detection and intelligent prediction [5] International Expansion - Sansure Biotech is focusing on international markets, signing agreements in Europe and collaborating with health authorities in Africa and Southeast Asia [7][8] - The company is also involved in projects to improve cervical cancer screening in Sierra Leone and training programs in Mongolia [8]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688289 证券简称：圣湘生物 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 (二) 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 持股5%以上股东、前10名股东及前10名无限售流通股股东参与转 ...

Core Viewpoint - The company, Shengxiang Biotechnology, reported steady growth in its financial performance for 2024 and Q1 2025, with significant increases in revenue and net profit, alongside strategic acquisitions to enhance its market position in the life sciences sector [1][5]. Financial Performance - In 2024, the company achieved a revenue of 1.458 billion yuan and a net profit of 276 million yuan, both meeting expectations; the non-recurring net profit increased by 182% year-on-year [1]. - For Q1 2025, the company reported a revenue of 475 million yuan, a 22% year-on-year increase, and a net profit of approximately 91.74 million yuan, up 13% [1][5]. - The company plans to distribute a cash dividend of 2.75 yuan per 10 shares, totaling around 158 million yuan, raising the total dividend for 2024 to over 300 million yuan [1]. Strategic Acquisitions - In 2025, the company initiated a series of acquisitions, including an 807.5 million yuan purchase of 100% equity in Zhongshan Haiji, entering the biopharmaceutical growth hormone sector [5][6]. - The company also invested 75.6 million yuan for a 54% stake in Hong'an Jiyuan and 130 million yuan in Zhenmai Biotechnology to enhance its capabilities in blood cell testing and gene sequencing [6]. - These acquisitions are supported by a strong cash flow, with a net cash flow from operating activities of 274 million yuan in 2024, a 530.34% increase year-on-year [6]. Technological Advancements - In 2024, the company invested 361 million yuan in R&D, a 53% increase, representing about 25% of its revenue, and obtained over 200 new domestic and international certifications and patents [2]. - The company made significant progress in key areas such as respiratory diseases, maternal and child health, and blood source testing, with new products launched and certifications obtained [2][3]. - The company is also focusing on AI applications in healthcare, developing a smart infectious disease system that integrates cloud, IoT, big data, and AI technologies for automated detection and monitoring [3][4]. Market Expansion and Service Model - Shengxiang Biotechnology is establishing a comprehensive medical service system that integrates hospitals, communities, and home care to enhance primary healthcare capabilities [4]. - The company has launched home testing services for respiratory pathogens in multiple provinces, promoting an "Internet + Healthcare" service model [4]. - Plans for 2025 include further international market investments and a commitment to localize operations while sharing Chinese experiences along the Belt and Road Initiative [6].

Core Viewpoint - The life science industry is experiencing new development opportunities driven by technological innovation and industry integration, with Shengxiang Biology establishing a solid foundation for growth through an efficient collaborative system and innovation-driven technological breakthroughs [1] Group 1: Company Overview - Shengxiang Biology is a provider of integrated diagnostic solutions, focusing on self-innovated gene technology, in vitro diagnostic reagents, instruments, third-party medical testing services, and biopharmaceuticals [2] - The company is transitioning towards becoming a leading international player in the life science sector [2] Group 2: Operational Efficiency - The company has established a matrix management system with vertical production lines in various fields, enabling deep collaboration across R&D, production, marketing, and technical services [2] - A rapid nucleic acid testing solution for respiratory diseases has been developed, allowing for quick detection of common flu-like cases within 40 minutes [2] Group 3: Technological Innovation - Shengxiang Biology's digital infectious disease system has been approved for a national digital transformation project, enhancing management efficiency and enabling multiple AI+ medical business scenarios [3] - The company has developed a comprehensive cervical cancer prevention product matrix and has achieved international leading performance in blood screening nucleic acid detection products [3][4] Group 4: R&D Investment - The company invests approximately 25% of its revenue in R&D, with 2024 R&D expenditure reaching 361 million yuan, a 53.36% increase year-on-year [4] - Shengxiang Biology has obtained nearly 1,800 domestic and international registrations and approvals, with over 1,400 active patents globally [4] Group 5: Customer-Centric Innovation - The company has established a multi-dimensional innovation system by collaborating with top hospitals and disease control centers to address clinical needs [5] - A comprehensive health service system has been developed, integrating R&D, production, and application across various regions [5] Group 6: Industry Ecosystem - Shengxiang Biology aims for diversified and international development, focusing on key technological innovations and market resource complementarity [6] - The company is enhancing its international strategy by optimizing product combinations and market strategies based on local conditions [6] Group 7: Integrated Diagnostic Layout - The company's integrated diagnostic layout focuses on in vitro diagnostics and biomanufacturing, with advancements in immunology, sequencing, and smart technologies [7] - Strategic investments in companies like QuantuMDx and First Light Diagnostics are accelerating the industrial transformation process [7]

（二） 股东大会召集人：董事会 证券代码：688289 证券简称：圣湘生物 公告编号：2025-031 圣湘生物科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 5 月 20 日 14 点 30 分 召开地点：上海市闵行区华西路 680 号（圣湘生物上海产业园） （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 20 日 至2025 年 5 月 20 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 股东大会召开日期： ...

证券代码：688289 证券简称：圣湘生物 公告编号：2025-027 圣湘生物科技股份有限公司（以下简称"公司"）第二届监事会 2025 年第三次会 议于 2025 年 4 月 28 日以现场方式召开，会议通知已于 2025 年 4 月 18 日以书面方式 送达全体监事。会议由监事会主席谭寤女士主持，应出席监事 3 人，实际出席监事 3 人。本次会议的通知、召开及审议程序符合《中华人民共和国公司法》（以下简称"《公 司法》"）和《公司章程》的有关规定。 二、监事会会议审议情况 经与会监事审议，一致通过如下议案： 1、审议通过了《圣湘生物科技股份有限公司 2024 年度监事会工作报告》 内容：2024 年度，监事会严格按照《公司法》《中华人民共和国证券法》等法律 法规和《公司章程》《监事会议事规则》等公司相关制度的规定，认真履行法律法规 赋予的职能，依法独立行使职权。监事通过参加公司股东会、列席董事会等形式，对 公司财务、经营决策、依法运作、董事及高级管理人员的决策和行为进行了认真监察 和监督，促进公司规范运作，维护了公司和全体股东的合法权益。 圣湘生物科技股份有限公司 第二届监事会 2025 年第三次会议决 ...

证券代码：688289 证券简称：圣湘生物 公告编号：2025-026 圣湘生物科技股份有限公司 第二届董事会 2025 年第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 圣湘生物科技股份有限公司（以下简称"公司"）第二届董事会 2025 年第五次 会议于 2025 年 4 月 28 日以现场结合通讯方式召开，会议通知已于 2025 年 4 月 18 日 以邮件方式送达全体董事。会议由董事长戴立忠先生主持，应出席董事 11 人，实际 出席董事 11 人。会议的通知、召开及审议程序符合《中华人民共和国公司法》（以 下简称"《公司法》"）和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事审议，一致通过如下议案： 1、审议通过了《圣湘生物科技股份有限公司 2024 年度董事会工作报告》 内容：2024 年度，公司董事会全体成员严格依据《公司法》《中华人民共和国证 券法》等法律法规和《公司章程》《董事会议事规则》等公司相关制度的规定，切实 履行股东大会赋予董事会的各项职责，认 ...

证券代码：688289 证券简称：圣湘生物 公告编号：2025-028 圣湘生物科技股份有限公司 关于 2024 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配比例：每 10 股派发现金红利 2.75 元（含税）。 本次利润分配以圣湘生物科技股份有限公司（以下简称"公司"）实施权益分 派的股权登记日登记的公司总股本扣减公司回购专用证券账户中股份为基数，具体日 期将在权益分派实施公告中明确。 如在实施权益分派的股权登记日前公司总股本扣减公司回购专用账户中股份 的基数发生变动的，拟维持每股分配比例不变，相应调整分配总额。 本次年度利润分配方案不会触及《上海证券交易所科创板股票上市规则》（以 下简称"《科创板股票上市规则》"）第 12.9.1 条第一款第（八）项规定的可能被实 施其他风险警示的情形。 如在本公告披露之日起至实施权益分派股权登记日期间，公司总股本扣减公司回 购专用账户中股份的基数发生变动的，拟维持每股分配比例不变，相应调整分配总额。 如后续总股本发生变化，公司将另行 ...

西部证券股份有限公司（以下简称"西部证券"或"保荐人"）作为圣湘生物科 技股份有限公司（以下简称"圣湘生物"或"公司"）首次公开发行股票并在科创板 上市的保荐人，根据《上海证券交易所科创板股票上市规则（2024 年 4 月修订）》 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》《科创板上市公司持续监管办法（试行）》等法律法规和规范性文件 的要求，对圣湘生物 2024 年度募集资金存放与使用情况进行了审慎核查，核查 情况如下： 一、首次公开发行股票募集资金的基本情况 （一）实际募集资金金额、募集完成时间 根据中国证券监督管理委员会《关于同意圣湘生物科技股份有限公司首次公 开发行股票注册的批复》（证监许可〔2020〕1580 号），公司获准向社会公开发 行人民币普通股 40,000,000 股，每股发行价格为人民币 50.48 元，募集资金总额 为 201,920.00 万元；扣除承销及保荐费用、发行登记费以及其他交易费用共计 14,993.02 万元（不含增值税金额）后，募集资金净额为 186,926.98 万元，上述资 金已全部到位，经中审众环会计师事务所（特殊普通 ...